The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma
- PMID: 17340210
- DOI: 10.1007/s11255-006-9159-5
The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma
Abstract
Objective: To evaluate the relationship between the expression of E-cadherin (E-CD) and tumor recurrence and progression in patients with high-grade stage T1 urothelial carcinoma of bladder.
Methods: Fifty-two patients who had primary high-grade stage T1 urothelial carcinoma were enrolled to the study. The pathologic specimens of patients were evaluated and staged as T1a and T1b according to muscularis mucosae involvement by the tumor. The immunohistochemical demonstration of E-CD was accomplished by using immunoperoxidase method and all the specimens were examined under light microscope for E-CD level.
Results: The mean age of the patients was 64.0 +/- 7.7 (range 36-81) years. The mean follow-up period was 56.4 +/- 19.4 (range 14-84) months. Among 52 patients, 27 (52%) of them were stage T1b and 25 (48%) were T1a tumors. The recurrence rates for T1a and T1b groups were 52% (n = 13) and 92.6% (n = 25), respectively (P < 0.05). The expression of E-CD was homogenous in 52% of pT1a and 14.8% of T1b tumors (P < 0.05). In T1a group with recurrence, homogeneous E-CD staining ratio was 30.7% (n = 4/13), but it was 75% (n = 9/12) in T1a patients without recurrence (P < 0.05). In T1b group with recurrence, the homogenous expression of E-CD was 12% (n = 3/25) and the expression of E-CD was heterogenous in 88% (n = 22/25) of them (P < 0.05). In T1a group, progression of the disease was detected in 28% (n = 7/25) of the patients, but disease progression was seen in 55.5% (n = 15/27) of T1b group patients (P < 0.05). In T1a group with progression, heterogeneous E-CD staining ratio was 85.7% (n = 6/7), but it was 80% (n = 12/15) in T1b patients with progression. The effects of tumor number, tumor size and carcinoma in situ presence on recurrence were evaluated within each group. It was determined that parameters such as tumor number and tumor size had no significant effect on recurrence of the groups. The mean survival rates were statistically different between the groups. On multivariate analysis only E-cadherin expression (P = 0.012, odds ratio 6.291, 95% confidence interval for odds ratio 1.303-4.72) and tumor stage (P = 0.003, odds ratio 11.58, 95% confidence interval for odds ratio 2.446-8.542) remained independently significant as predictors of recurrence.
Conclusion: E-CD expression was decreased in pathologic specimens of bladder tumor patients with muscularis mucosae involvement and this condition correlated well with tumor recurrence.
Similar articles
-
Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?Urol Int. 2008;80(4):413-8. doi: 10.1159/000132700. Epub 2008 Jun 27. Urol Int. 2008. PMID: 18587253 Clinical Trial.
-
Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression.Cancer. 2004 Jun 1;100(11):2367-75. doi: 10.1002/cncr.20306. Cancer. 2004. PMID: 15160340
-
Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma.J Urol. 2000 Apr;163(4):1120-3. J Urol. 2000. PMID: 10737479
-
Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer.J Urol. 2004 Jan;171(1):149-52. doi: 10.1097/01.ju.0000099825.98542.a8. J Urol. 2004. PMID: 14665864 Review.
-
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis.World J Urol. 2020 Jun;38(6):1437-1449. doi: 10.1007/s00345-019-02936-y. Epub 2019 Sep 6. World J Urol. 2020. PMID: 31493109 Free PMC article.
Cited by
-
Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study.World J Urol. 2017 Jan;35(1):113-120. doi: 10.1007/s00345-016-1835-1. Epub 2016 Apr 29. World J Urol. 2017. PMID: 27129576 Free PMC article.
-
Reduced E-cadherin expression is correlated with poor prognosis in patients with bladder cancer: a systematic review and meta-analysis.Oncotarget. 2017 Aug 4;8(37):62489-62499. doi: 10.18632/oncotarget.19934. eCollection 2017 Sep 22. Oncotarget. 2017. PMID: 28977963 Free PMC article.
-
The study of miRNA-200c expression and epithelial-to-mesenchymal transition-related transcription factors in the primary bladder urothelial carcinoma.Urol Ann. 2023 Jan-Mar;15(1):35-42. doi: 10.4103/ua.ua_72_22. Epub 2022 Nov 8. Urol Ann. 2023. PMID: 37006208 Free PMC article.
-
Is Immunohistochemical Galectin-3 Expression Associated with the Epithelial-Mesenchymal Transition in High- and Low-Grade Invasive Urothelial Carcinomas of the Bladder?Diagnostics (Basel). 2024 Oct 12;14(20):2270. doi: 10.3390/diagnostics14202270. Diagnostics (Basel). 2024. PMID: 39451592 Free PMC article.
-
Plasmacytoid Urothelial Carcinoma of the Bladder That Manifests Disseminated Carcinomatosis of the Bone Marrow: A Case Report of Extremely Rapid Progression.Case Rep Urol. 2022 Sep 15;2022:6082700. doi: 10.1155/2022/6082700. eCollection 2022. Case Rep Urol. 2022. PMID: 36157380 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical